NONCONTROLLING INTERESTS |
6 Months Ended | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2026 | ||||||||||||||||
| Noncontrolling Interest [Abstract] | ||||||||||||||||
| NONCONTROLLING INTERESTS | NOTE 13 – NONCONTROLLING INTERESTS
The Company holds an 83% controlling interest in GEAR Therapeutics, Inc., and the remaining 17% is held by noncontrolling interests. The Company acquired its interest in GEAR on the Closing Date in connection with the Merger; accordingly, GEAR’s results are included in the condensed consolidated financial statements as of April 24, 2026. GEAR is consolidated, and the portion of GEAR’s net loss and equity attributable to the noncontrolling interests is presented separately in the condensed consolidated statements of operations and within stockholders’ equity.
In connection with the Merger, the noncontrolling interest in GEAR was measured at its acquisition-date fair value of $72,250. See Note 4.
From the Closing Date through June 30, 2026, net loss attributable to the noncontrolling interests was $72,250, representing the noncontrolling interests’ 17% share of GEAR’s net loss for that period. The following table summarizes the changes in the noncontrolling interests for the period from the Closing Date to June 30, 2026:
|